Ipamorelin
Selective GH secretagogue (pentapeptide)Studied in: selective growth-hormone release models.
← Catalog · Research overview
CJC-1295 research overview
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), modified to last longer in circulation.
- CLASS
- GHRH analog
- FORM
- Lyophilized powder
- TESTING
- HPLC purity and mass-spec identity by an independent lab — COA published per batch
- STORAGE
- −20 °C, dry, protected from light
What it is
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), modified to last longer in circulation.
What researchers have studied
CJC-1295 has been explored in growth-hormone-releasing-hormone signaling. Published research includes:
- Extended GH and IGF-1 signaling in published pharmacology studies
- Pulsatile GH release in laboratory research
- Often studied alongside GH secretagogues such as ipamorelin
GH Axis research
Peptides that act on the growth-hormone signaling pathway, studied for how they influence GH release in laboratory models.
This page summarizes published laboratory and animal (preclinical) research for educational purposes. It is not a claim of safety or effectiveness in humans. CJC-1295 from Nova Peptide Solutions will be sold strictly for in-vitro laboratory research. Not evaluated by the FDA. Not for human or animal consumption, and not intended to diagnose, treat, cure or prevent any disease.
Related research compounds
Sermorelin
GHRH (1–29) analogStudied in: pituitary growth-hormone signaling.